12 Dividend Stocks With High Insider Buying
Dividend policy has taken the spotlight again among the investors’ discussions in the U.S.
Insider Monkey Blog
10 AI Stocks to Watch: Broadcom, AMD, and More
According to Gartner, Inc., a business and technology insights company, global spending on artificial intelligence is forecast to total $2.52 trillion in 2026, a 44% increase ...
Hedge Fund and Insider Trading News: George Soros, Bill Ackman, Warren Buffett, Steve Cohen, Elliott Management, L1 Capital, Citadel Investment Group, Mattel Inc (MAT), and More
You may be concerned about the recent declines in AI stocks such as NVDA.
11 Best Canadian Growth Stocks to Buy According to Hedge Funds
For over 10 years, U.S. equities have dominated global markets, but that leadership is beginning to show signs of fatigue in 2025. Valuation gaps illustrate the shift: U.S.
11 Best Entertainment Stocks to Buy According to Wall Street
Entertainment stocks are back in the conversation as investors look beyond the narrow list of sectors that defined much of the past two years.
Arcellx (ACLX) Shares Encouraging Data on Latest Laboratory Study
On February 12, Qize Ding from Rothschild & Co Redburn downgraded the rating on Arcellx Incorporated (NASDAQ:ACLX) from Buy to Neutral.
Here is Why Apogee Therapeutics (APGE) Appears Attractive
On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics (NASDAQ:APGE), with a $95 price target.
Atacicept’s Potential Approval Drives Favorable Views on Vera Therapeutics (VERA)
Rama believes the shares offer strong upside potential from the current trading range.
Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026
As of the close of play on February 12, consensus sentiment around Spyre Therapeutics (NASDAQ:SYRE) was strongly bullish.
Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX)
On February 10, Guggenheim analyst Yatin Suneja raised the price target on Praxis Precision Medicines (NASDAQ:PRAX) from $760 to $800.
Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA)
On January 29, Danielle Brill from Truist Financial raised her price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $33 to $38 and assigned a Buy rating to the stock.
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating
On February 11, Laura Prendergast of Stifel Nicolaus initiated coverage of Olema Pharmaceuticals (NASDAQ:OLMA).
Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)
On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, who maintained a Buy rating on the stock.
Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program
As of the February 12 closing, consensus sentiment around Wave Life Sciences (NASDAQ:WVE) remained strongly bullish.
13 Most Profitable Software Stocks to Buy Now
In this era of global technology transformation, software companies have had their fair share of traction, and rightly so! However, these companies have recently been in the spotlight...
Summit Therapeutics (SMMT) Grabs Investor Attention After Major FDA Breakthrough
As of the close of play on February 12, consensus sentiment around Summit Therapeutics (NASDAQ:SMMT) was moderately bullish.
FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN)
On January 20, Leonid Timashev of RBC Capital maintained an Outperform rating on Legend Biotech (NASDAQ:LEGN) and set a $66 price target.
What Makes BioMarin (BMRN) so Attractive
As of February 12 closing, BioMarin Pharmaceutical (NASDAQ:BMRN) carried a moderately bullish analyst sentiment.
Soleno Therapeutics (SLNO) Sparks Confidence Amid Topline Outperformance
On January 20, the price target on Soleno Therapeutics (NASDAQ:SLNO) was increased from $110 to $120 by Ram Selvaraju from H.C. Wainwright.
FDA-Issued CRL for Relacorilant NDA Leads to Bullish Views Around Corcept Therapeutics (CORT)
On February 2, Edward Nash from Canaccord Genuity reaffirmed his Buy rating for Corcept Therapeutics (NASDAQ:CORT).
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry
As of the February 12 closing, Dyne Therapeutics (NASDAQ:DYN) held a strongly bullish consensus view.
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)
On January 23, Cantor Fitzgerald maintained its Overweight rating on Vaxcyte Incorporated (NASDAQ:PCVX), highlighting continued progress across the company’s clinical pipeline...
Here is Why Beam Therapeutics (BEAM) Appears so Attractive
On January 22, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Beam Therapeutics (NASDAQ:BEAM), with a price target of $80.
11 Best Bitcoin and Blockchain Stocks to Invest in
Bitcoin plummeted below $61,000 on February 5, reversing all gains since US President Donald Trump's election in November 2024, as reported by Reuters on February 7, 2026.
Hedge Fund Investor Letters Q4 2025
We will be sharing Q4 2025 hedge fund investor letters in this article.
UBS Still Neutral on East West Bank (EWBC)
UBS, on February 4, marginally trimmed its target price on East West Bancorp (EWBC) to $125 (from $126).
UBS Retained Buy Recommendation on SouthState Bank (SSB)
On February 4, UBS slightly increased its target price on SouthState Bank (SSB) to $121 (from $120) and reiterated its Buy recommendation.
Commerce Bank (CBSH) Declares Dividends of $0.2750 per Share
On February 6, the board of directors of Commerce Bancshares (CBSH) declared a quarterly dividend of $0.2750 per share.
UBS Keeps Buy Rating on Western Alliance (WAL)
On February 4, UBS trimmed its target price on Western Alliance (WAL) by 0.9% to $106 (from $107) but retained its Buy recommendation on the stock.
JP Morgan Increases Target Price on Huntington Bancshares (HBAN) to $21
On February 9, JPMorgan analyst Andrew Dietrich raised his target price on Huntington Bancshares by 5.0% to $21 (from $20) and kept his Overweight call on the stock.
Evercore ISI Raises Price Target on Pinnacle Financial (PNFP) to $116, Keeps Overweight Call
On February 6, Evercore ISI raised its target price on Pinnacle Financial by 0.9% to $116 (from $115) and retained its Outperform call on the stock.
JP Morgan Raises Target Price on Truist Financial (TFC) to $47, Keeps Neutral Call
On February 9, JPMorgan analyst Vivek Juneja raised his target price on Truist Financial by 10.7% to $57.00 (from $51.50) but maintained his Neutral rating on the stock.
JP Morgan Overweight on BNY Mellon (BK) with a Target Price of $128.50
JPMorgan raised its target price on BNY Mellon by 2.8% to $128.50 (from $125.00), while reiterating the firm’s Overweight call on the stock.
Baird Upgrades Wells Fargo (WFC) to Neutral
Baird, on February 13, upgraded Wells Fargo to a Neutral (from Underperform). Despite the rating upgrade, the firm did not change its $85 target price on the company.
JP Morgan Raises Target Price on Citi (C), Keeps Overweight Call
On February 9, JPMorgan raised its target price on Citi by 3.1% to $134 (from $130), reiterating its Overweight rating on the stock.
Taiwan Semiconductor Manufacturing (TSM) Positioned to Benefit From AI Demand and Potential Pricing Power
Sands Capital Management, LLC's Technology Innovators Fund released its Q4 2025 investor letter for "Technology Innovators Fund". A copy of the letter can be downloaded here.
Swiss Firmup Launches as a Prop Firm Focused on Transparent Futures Trading
Swiss Firmup today announces its launch as a proprietary trading firm dedicated to supporting independent traders operating in the global financial derivatives markets.
Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling
Arquitos Capital Partners, an investment management firm, released its Q4 2025 investor letter. A copy of the letter can be downloaded here.
10 Best S&P 500 Stocks With Highest Upside Potential
The S&P 500 index’s drop was muted in comparison to the Dow. The broad-based market index retreated less than a point to finish the day at 6,941.47.
Fabrinet (FN) Advances as Optical Hardware Demand Strengthens
Wasatch Global Investors, an asset management company, released its "Small Cap Growth Strategy" Q4 2025 investor letter. A copy of the letter can be downloaded here.
JFrog (FROG) Gains Momentum Following 26% Revenue Growth Beat
Wasatch Global Investors, an asset management company, released its "Small Cap Growth Strategy" Q4 2025 investor letter. A copy of the letter can be downloaded here.
Trex Company (TREX) Under Pressure as Housing Weakness Impacts Outdoor Living Demand
Wasatch Global Investors, an asset management company, released its "Small Cap Growth Strategy" Q4 2025 investor letter. A copy of the letter can be downloaded here.
Shift4 Payments (FOUR) Remains in Focus Amid Volatility in Payment Technology Stocks
Wasatch Global Investors, an asset management company, released its "Small Cap Growth Strategy" Q4 2025 investor letter. A copy of the letter can be downloaded here.
10 Best Performing Foreign Stocks to Buy Now
On January 6, Tim Seymour of Seymour Asset Management appeared on a CNBC Television interview to discuss whether the international markets rally has legs to continue in 2026...
Vital Farms (VITL) Faces Short-Term Pressure Despite Continued Demand for Ethical Food Products
Wasatch Global Investors, an asset management company, released its "Small Cap Growth Strategy" Q4 2025 investor letter. A copy of the letter can be downloaded here.
RBC Bearings (RBC) Remains a Core Holding Amid Expectations for 2026 Growth
Wasatch Global Investors, an asset management company, released its "Small Cap Growth Strategy" Q4 2025 investor letter. A copy of the letter can be downloaded here.
10 Best Bank Stocks to Buy in 2026
Bloomberg reported on February 12 that the US Federal Reserve is signaling to banks that it plans to drop some of its prior warnings (also known as matters requiring attention...
Ares Management Corp (ARES) Deepening Exposure to the AI Space
Ares Management Corp (NYSE:ARES) is one of the best NYSE stocks to buy for the long term.
Snap Inc (SNAP) Pivoting to Profitable Growth
Snap Inc (NYSE:SNAP) is one of the best NYSE stocks to buy for the long term.
Celestica Inc (CLS): Analysts Bullish Amid Strong 2026 Outlook
Celestica Inc (NYSE:CLS) is one of the best NYSE stocks to buy for the long term. Celestica Inc (NYSE:CLS) reported its Q4 2025 earnings on January 28.
Hedge Fund Resource Center
